About this trial
PD Frontline (part of RAPSODI GD) is an online study observational study with the goal of bringing People with Parkinson's to the frontline of research by getting them trial ready. To do this, participants are offered genetic sequencing for the GBA and LRRK2 gene with an at-home saliva collection kit.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Formal diagnosis of Parkinson Disease
Disqualifiers
Confirmation that the individual carries a GBA variant (GBA positive). These individuals will be referred to sister-study, RAPSODI.
History of Parkinsonism (progressive supranuclear palsy, multiple system atrophy, traumatic, manganese toxicity, postencephalitic, vascular PD; drug induced PD; corticobasal degeneration)
Individuals with another neurological disorder including: dementia, movement disorders, and motor neurone disease.
Individuals on drugs known to be associated with parkinsonism, including neuroleptic agents (Amisulpride, Chlorpromazine Hydrochloride, Flupenthixol, Fluphenazine Hydrochloride, Haloperidol, Methotrimeprazine, Levomepromazine, Olanzapine, Oxypertine, Pericyazine, Perphenazine, Pimozide, Pipotiazine, Prochlorperazine, Promazine Hydrochloride, Reserpine, Risperidone, Sulpiride, Thioridazine, Trifluoperazine, Zuclopenthixol acetate, Zotepine), plus Bupropion, , Lithium, Methyldopa, Metoclopramide and Sodium Valproate).
Trial population
Randomly selected population, recruited via established NHS sites and self-referral to the website.
Trial design
Cohort
Other
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Genotype of participants
The primary outcome of the study is to genotype the GBA1 gene, obtained with Oxford Nanopore long read sequencing.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University College London Hospitals
Lead sponsor
Cure Parkinson's
Collaborator